Investor Value Proposition

Trillium is developing the next-generation of cancer immunotherapies. Our lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a "do not eat" signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed as a therapy for acute myeloid leukemia but also holds promise as a treatment for other hematological and solid tumors.

Recent Presentations

Thumb Date Download
Apr 03, 2017 AACR 2017 Abstract #2646 9.96 MB
Apr 03, 2017 AACR 2017 Abstract #2653 720 KB
Feb 24, 2017 ASCO-SITC 2017 839 KB

Investor FAQ

Where can I find the current share price?


The current share price can be found by searching for the ticker symbol “TRIL” at and at


Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.